armagen-logo brain  
 
HomeAbout the BBB
Targeting
ProductsNewsCareersContact Us
 
 

The blood-brain barrier blocks the development of biologic pharmaceuticals for brain 

ArmaGen provides platform technology solutions to the 'blood-brain barrier' problem, and can non-invasively target recombinant proteins, therapeutic monoclonal antibodies, and siRNA to the brain


slideshow

 

home_pic
Brain blood vessels form the blood-brain barrier and block drug access to the brain

 

News    April 10, 2009

ArmaGen plans First in Human clinical trial

cGMP Manufacturing. ArmaGen’s lead therapeutic is a genetically engineered fusion protein of a neurotrophin and an engineered monoclonal antibody. The antibody crosses the human blood-brain barrier (BBB) and acts as a molecular Trojan horse to carry into brain the attached neuroprotective neurotrophin. In preparation.....

  more news

Home | About the BBB | Targeting - Protein Drugs . Non-Viral Genes . Small Molecules | Products | News | Careers | Contact Us